The FDA approved nivolumab as adjuvant treatment for certain patients with completely resected esophageal or gastroesophageal junction cancers, according to the agent’s manufacturer. The approval ...

Opdivo was approved by the FDA for use if disease persisted after neoadjuvant chemoradiotherapy in these patients, which is “exciting news,” as patients would typically undergo surveillance when this ...

Tevimbra plus chemotherapy reduced the risk of death by 20% compared with placebo plus chemotherapy. The Food and Drug Administration (FDA) has approved Tevimbra ® (tislelizumab-jsgr) for use in ...

Opdivo is a programmed death receptor-1 blocking antibody. (Credit: Getty Images.) The Food and Drug Administration (FDA) has approved Opdivo® (nivolumab) for the adjuvant treatment of completely ...

The transition from the esophagus to the stomach is a delicate region from a medical point of view, often associated with pathological disorders leading to cancer. An international research team has ...

Lower Incidence of Colorectal Cancer and Later Age of Disease Onset in 27 Families With Pathogenic MSH6 Germline Mutations Compared With Families With MLH1 or MSH2 Mutations: The German Hereditary ...

It is ambiguous as to whether long-term PPI therapy significantly reduces the length of the Barrett's segment in patients with Barrett's esophagus. This single-center study analyzed data collected ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio The addition of nivolumab to chemotherapy ...

Cancers of the upper gastrointestinal (GI) tract form a heterogeneous group of diseases for which treatment paradigms for localized disease continue to emerge. The management for localized disease is ...

Esophageal cancer causes more than half a million deaths each year. Neoadjuvant chemoradiotherapy followed by surgery is a widely used standard of care in resectable, locally advanced esophageal or ...

Purpose: Patients diagnosed with esophageal adenocarcinoma (EAC) or gastroesophageal junction adenocarcinoma (GEJAC) have poor survival. We investigated the possible influence of pre-morbid lifestyle ...